January 10, 2022

Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy SHANGHAI, China, and REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., […]

Successful performance of plasma compression prototype confirms path to commercialization General Fusion’s plasma compression prototype VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — General Fusion announced today it has successfully achieved several aggressive performance goals of a prototype system for its Fusion Demonstration Plant (FDP). The company’s plasma compression prototype, located at its Vancouver, […]

BEIJING and LONDON and PARIS and SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) — After overwhelming demand, creative offers and global inquires from it’s recent September 2021 billion dollar auction, A4BET® is announcing a time sensitive bidding process to acquire this rare, unique, valuable name. A4BET® covers everything from A-Z! The sale of A4BET® includes: […]

CHIPPENHAM, United Kingdom, Jan. 10, 2022 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that UK-based sports and hobbies retailer Fishing Tackle & Bait has successfully transformed its international fulfillment capabilities with Descartes’ cloud-based ecommerce warehouse management solution (WMS). With Descartes, the multi-channel […]

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical […]

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral infection on the point-of-need platform MeMed Key® HAIFA, Israel; BOSTON, MA; January 10th, 2022 – MeMed, a leader in host response technologies, today announces a $93 million […]

Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep […]